12:00 AM
 | 
Jul 01, 2013
 |  BC Week In Review  |  Company News  |  Deals

Pearl Therapeutics, AstraZeneca deal

AstraZeneca completed the acquisition of Pearl for $560 million up front. Pearl will be eligible for up to $450 million in development and regulatory milestones, plus...

Read the full 106 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >